Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
2001 1
2002 1
2007 3
2008 2
2009 5
2010 5
2011 8
2012 2
2013 11
2014 11
2015 8
2016 9
2017 13
2018 8
2019 14
2020 21
2021 29
2022 27
2023 29
2024 23
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
Montalban X, Lebrun-Frénay C, Oh J, Arrambide G, Moccia M, Pia Amato M, Amezcua L, Banwell B, Bar-Or A, Barkhof F, Butzkueven H, Ciccarelli O, Chataway J, Cohen JA, Comi G, Correale J, Deisenhammer F, Filippi M, Fiol J, Freedman MS, Fujihara K, Granziera C, Green AJ, Hartung HP, Hellwig K, Kappos L, Kimbrough D, Killestein J, Lublin F, Marignier R, Ann Marrie R, Miller A, Otero-Romero S, Ontaneda D, Ramanathan S, Reich D, Rocca MA, Rovira À, Saidha S, Salter A, Sastre-Garriga J, Saylor D, Solomon AJ, Sormani MP, Stankoff B, Tintore M, Tremlett H, Van der Walt A, Viswanathan S, Wiendl H, Wildemann B, Yamout B, Zaratin P, Calabresi PA, Coetzee T, Thompson AJ. Montalban X, et al. Among authors: lebrun frenay c. Lancet Neurol. 2025 Oct;24(10):850-865. doi: 10.1016/S1474-4422(25)00270-4. Lancet Neurol. 2025. PMID: 40975101 Review.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Radiologically isolated syndrome.
Lebrun-Frenay C, Kantarci O, Siva A, Azevedo CJ, Makhani N, Pelletier D, Okuda DT. Lebrun-Frenay C, et al. Lancet Neurol. 2023 Nov;22(11):1075-1086. doi: 10.1016/S1474-4422(23)00281-8. Epub 2023 Oct 12. Lancet Neurol. 2023. PMID: 37839432 Review.
The radiologically isolated syndrome: revised diagnostic criteria.
Lebrun-Frénay C, Okuda DT, Siva A, Landes-Chateau C, Azevedo CJ, Mondot L, Carra-Dallière C, Zephir H, Louapre C, Durand-Dubief F, Le Page E, Bensa C, Ruet A, Ciron J, Laplaud DA, Casez O, Mathey G, de Seze J, Zeydan B, Makhani N, Tutuncu M, Levraut M, Cohen M, Thouvenot E, Pelletier D, Kantarci OH. Lebrun-Frénay C, et al. Brain. 2023 Aug 1;146(8):3431-3443. doi: 10.1093/brain/awad073. Brain. 2023. PMID: 36864688 Free PMC article.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial.
Thouvenot E, Laplaud D, Lebrun-Frenay C, Derache N, Le Page E, Maillart E, Froment-Tilikete C, Castelnovo G, Casez O, Coustans M, Guennoc AM, Heinzlef O, Magy L, Nifle C, Ayrignac X, Fromont A, Gaillard N, Caucheteux N, Patry I, De Sèze J, Deschamps R, Clavelou P, Biotti D, Edan G, Camu W, Agherbi H, Renard D, Demattei C, Fabbro-Peray P, Mura T, Rival M; D-Lay MS Investigators. Thouvenot E, et al. Among authors: lebrun frenay c. JAMA. 2025 Apr 22;333(16):1413-1422. doi: 10.1001/jama.2025.1604. JAMA. 2025. PMID: 40063041 Free PMC article. Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D. Okuda DT, et al. Among authors: lebrun frenay c. Ann Neurol. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10. Ann Neurol. 2023. PMID: 36401339 Clinical Trial.
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Otero-Romero S, Lebrun-Frénay C, Reyes S, Amato MP, Campins M, Farez M, Filippi M, Hacohen Y, Hemmer B, Juuti R, Magyari M, Oreja-Guevara C, Siva A, Vukusic S, Tintoré M. Otero-Romero S, et al. Among authors: lebrun frenay c. Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9. Mult Scler. 2023. PMID: 37293841 Free PMC article.
Infectious myelitis.
Lebrun Frenay C. Lebrun Frenay C. Rev Neurol (Paris). 2019 Sep-Oct;175(7-8):464-468. doi: 10.1016/j.neurol.2019.07.001. Epub 2019 Jul 30. Rev Neurol (Paris). 2019. PMID: 31375285 Review.
225 results